Beta 2 agonists have adverse systemic effects if administered in high doses. This may be relBackground -The main adverse effects of 2 agonists relate to their systemic activity. evant to the two most recent epidemics of asthma deaths since the agonists implicated The time course and dose response relations of the systemic effects of salmeterol -isoprenaline and fenoterol -were administered as high dose formulations compared compared with salbutamol were investigated.
QT c interval (QT interval corrected for heart and active drug metered dose inhalers. A separate set of six inhalers was used for each rate) were measured by 12-lead electrocardiography (ECG) (Marquette MAC II, subject and treatment period. The active inhalers contained 200 g salbutamol or 25 g Marquette Electronics Inc) programmed to calculate heart rate, QT c interval, and to detect a salmeterol per actuation. Each dose consisted of 16 actuations given as one actuation every change in T wave amplitude of >1 mm from the mean of five successive R-R intervals. Pulse 20 seconds and with the active treatments given last so that dosing was completed at the same rate, systolic and diastolic blood pressure were measured using a semi-automated sphygmo-time before subsequent measurements. Inhalers were primed before use by shaking and manometer (Narco Scientific BP203NA) with a standard width cuff. Venous blood samples dispelling four actuations into the air outside the investigation room. After actuating the inwere analysed in batches at the end of the study for plasma potassium concentrations by flame haler at functional residual capacity subjects inhaled to vital capacity and held their breath photometry (Olympus AU5000, Olympus Optical Company Limited, Eastleigh, UK) and for 10 seconds.
Timing was started immediately after the plasma glucose concentrations by hexokinase assay (Olympus AU800, Olympus Optical final inhalation and heart rate was measured at one minute intervals for the first 10 minutes. Company Limited, Eastleigh, UK) in the Department of Clinical Chemistry (City Hospital, Blood pressure and the QT c interval were measured at two and five minutes and heart rate, Nottingham).
QT c interval, blood pressure, plasma potassium and glucose concentrations were measured at 10, 20, 30, 45, 60, 90, 120, 150, 180, 210,  This was a double blind, placebo controlled, and 240 minutes after dosing. Measurements were always made in the same order -ECG seven way, crossover study with treatment order determined by a random code. A full medical followed by blood pressure and blood sampling.
Adverse events were assessed by asking subjects history, examination and laboratory screening tests were carried out on an initial screening "How are you?" at 30, 60, 120, and 240 minutes after dosing. visit and subjects had to show that they could use a metered dose inhaler correctly. They
The study was to be stopped and oral propranolol 10 mg given if there were clinically were asked to take no medication other than paracetamol for analgesia during the study important symptoms or if the heart rate rose above 140 bpm. With 14 subjects, the study period and to refrain from strenuous exercise or alcohol for 24 hours and from food, caffeinated had over 90% power to detect a difference of 7 bpm between any pair of treatments. beverages, and smoking from midnight prior to each visit. A drink of water was permitted on waking after which nothing was ingested until the end of the visit.
  
The maximum change from baseline and the Subjects attended the department at the same time on seven mornings with a washout maximum (minimum for plasma potassium concentration and diastolic blood pressure) abperiod of at least 72 hours between visits. An intravenous cannula (Butterfly 21G) was in-solute values following each dose of treatment were calculated for each measurement. For serted into a forearm vein and kept patent with heparinised saline and an automated sphygmo-all measurements from 10 minutes after drug administration treatment comparisons were manometer was placed on the opposite arm. Subjects were then attached to a 12-lead elec-made by multifactorial analysis of variance using period, treatment, and subjects as detrocardiogram. The ECG and blood pressure were recorded at five minute intervals until pendent variables. Log dose response curves were plotted for each end point. The mean stable baseline values were attained, defined as three consecutive readings of heart rate and heart rate during the first nine minutes was compared between treatments by analysis of blood pressure within 10 bpm and 10 mmHg, respectively. Blood was taken on two occasions variance. Seven of 1274 plasma potassium values exceeded 7.0 mmol/l, probably due to inbefore dosing for baseline plasma potassium and glucose assay.
correct placing in a fluoride bottle; these values were considered to be errors and were excluded Once baseline measurements were stable subjects inhaled either placebo, salmeterol from the analysis prior to unblinding. Adverse events were compared by the Fisher exact prob-(100, 200 or 400 g) or salbutamol (600, 1200 or 2400 g) from a combination of six placebo ability test. 12 If findings were not significant, an estimate of the relative dose potency of salmeterol compared with salbutamol was obtained with 95% confidence intervals (CI). If the curves were not parallel or not linear, salbutamol 600 g was compared with salmeterol 100 g, salbutamol 1200 g with salmeterol 200 g, and salbutamol 2400 g with salmeterol 400 g by paired t test. Analyses were carried out using a SAS statistical package.
Results
All 14 subjects, mean age 29.7 years (range 20-45), completed the study. Ten subjects were lifelong non-smokers, two were ex-smokers (less than five pack years), and two were current smokers (less than 10 cigarettes per day). Baseline values showed no significant treatment effect (table 1) .
  QT c interval, blood pressure, plasma potassium and glucose concentrations
Salbutamol and salmeterol caused a dose re- in QT c interval was rapid following both drugs, although the increase was more prolonged with salmeterol. The fall in the plasma potassium concentration and the increase in the plasma glucose concentration following salmeterol occurred more gradually and were more prolonged than those seen following salbutamol; the greatest difference in time to maximum effect occurred with the highest dose of both drugs (fig 1) . No dose related changes in systolic or diastolic blood pressure occurred with either drug.
Heart rate Both drugs caused a dose related increase in heart rate one minute after inhalation which was sustained over the following nine minutes (fig 2) . The maximum increase in heart rate occurred within 30-53 minutes for all doses of salbutamol and had largely disappeared by 240 minutes, whereas the maximum increase with salmeterol occurred between 75 and 135 minutes and values were still high at 240 minutes. The highest dose of salmeterol (400 g) caused a greater mean (SE) increase in heart rate (33 (4.3) bpm) and plasma glucose concentration (2.3 (0.36) mmol/l) than the highest dose of salbutamol (2400 g, 24 (1.5) bpm, and 1.6 (1.57) mmol/l). Salmeterol also produced the greatest individual changes in heart rate (59 bpm), plasma potassium concentration pared with salbutamol (36 bpm, −1.1 mmol/l, 3.5 mmol/l, and 182 ms, respectively).
Log dose response curves were tested for lack of linearity at the 5% level and for lack of   
The log dose response relationships for change parallelism at the 10% level over the dose range employed according to the methods of and for absolute values of heart rate (10-240 min), QT c interval, and plasma potas-with salmeterol 400 g than with salmeterol 200 g or salbutamol 2400 g. Salmeterol sium and glucose concentrations were linear (p>0.05) for both salmeterol and salbutamol 200 g and salbutamol 2400 g caused more adverse effects than placebo. There were no except for absolute heart rate (p=0.045) and plasma glucose concentration (p=0.019) significant differences in the frequency of adverse effects between placebo, salbutamol following salmeterol. For the measurements which produced a linear log dose response 600 g and 1200 g, or salmeterol 100 g. following both drugs, QT c interval and plasma potassium concentration did not deviate from parallelism (p>0.10) whilst changes in heart ECG changes Prolonged QT c interval, defined as >460 ms, rate (10-240 min) and plasma glucose concentration were significantly non-parallel (p= and T wave flattening occurred more commonly with the higher doses of 2 agonists and 0.013 and p=0.018, respectively), the response to salmeterol being steeper than that to sal-with salmeterol more than with salbutamol.
Other ECG changes included premature ventbutamol (figs 3 and 4).
The mean (95% CI) relative dose potency ricular beats (one salbutamol 2400 g) and first degree atrioventricular block (one placebo, one for change and absolute values of plasma potassium concentration of salmeterol compared salmeterol 100 g). with salbutamol were 8.2 (5.7 to 12.6) and 7.8 (5.9 to 10.5), and for change and absolute values of QT c interval were 7.1 (3.9 to 14.4) Discussion Inhalation of salmeterol and salbutamol caused and 6.5 (3.8 to 11.8).
For heart rate and plasma glucose con-dose dependent changes in heart rate, QT c interval, and plasma glucose and potassium centration salmeterol 100 g and 200 g did not differ significantly from salbutamol 600 g concentrations as expected from 2 agonists. and 1200 g, respectively; however, salmeterol 400 g caused a significantly greater increase in both measurements than salbutamol 2400 g  
The timing and magnitude of the changes in (p<0.01).
heart rate, QT c interval, plasma glucose and potassium concentrations following salbutamol were broadly similar to those seen in previous   Symptoms studies. 10 11 13 Inhaled salmeterol had a slower onset of action than salbutamol, although both Adverse events (particularly tremor and palpitations) occurred significantly more often drugs caused an early dose dependent increase in heart rate which was apparent after one sponses including insulin release and reduced glucagon production. In contrast, the increase minute and was sustained. The mean maximum increase in heart rate during the first 10 in heart rate and the fall in the plasma potassium concentration were sustained at four minutes when heart rate was recorded at one minute intervals was 19 bpm for salbutamol (at hours whilst the QT c interval had fallen slightly.
The absence of homeostasis for the 2 agonist one minute) and 17 bpm for salmeterol (at six minutes). Such a rapid and large increase in induced tachycardia is presumably because heart rate is predominantly controlled by symheart rate has not been documented previously with either drug. The increase in QT c interval pathetic tone and any compensatory increase in vagal tone would have a small effect at most. following both drugs was also rapid, whilst the changes in plasma potassium and glucose
We found no significant changes in blood pressure following either drug, in keeping with concentrations occurred more gradually. The rapid cardiac effects may therefore be due to some previous studies, 6 10 13 although others have shown a dose dependent increase in the a direct effect of the agonist on the heart following rapid absorption from the lung or, systolic blood pressure or a decrease in the diastolic blood pressure. [16] [17] [18] The differences possibly, the buccal mucosa, analogous to the bolus effect seen with intravenous ad-between studies may reflect differences in the efficiency of homeostatic control of blood presministration.
The early rise in heart rate with both 2 sure or confounding by other factors that affect blood pressure. agonists was followed by a further increase. This was particularly marked one to two hours after salmeterol 400 g and may in part be due to absorption of the swallowed fraction    The log dose response curves for QT c interval of inhaled salmeterol from the gastrointestinal tract. Both drugs were given by metered dose and plasma potassium concentration were linear and parallel whereas those for heart rate inhaler without a spacer so that some 80% of the drug is likely to have been swallowed. 14 and plasma glucose concentration were steeper for salmeterol than for salbutamol. This meant Peak plasma concentrations of salmeterol and salbutamol usually occur one hour after an oral that we could only calculate a relative dose potency for salmeterol compared with saldose (Glaxo Wellcome data on file). 15 The plasma glucose concentration had re-butamol for change in QT c interval and plasma potassium concentration; the figures we obturned towards baseline at four hours after salmeterol, presumably due to homeostatic re-tained, 7.1 and 8.2, respectively, are similar group.bmj.com on May 1, 2017 -Published by http://thorax.bmj.com/ Downloaded from to our previous estimates in man. 10 11 There QT c interval. The most likely explanation is that the doses of salbutamol given were inwas no significant difference in heart rate or glucose between the low and medium doses of sufficient to reach the steep part of the dose response curves, although similar doses apthe two 2 agonists whereas salmeterol 400 g caused a significantly greater maximum chron-peared to produce heart rate responses on the linear portion of the log dose response curve otropic and hyperglycaemic response than salbutamol 2400 g. The frequency of adverse in previous studies. 10 11 Alternatively, the high lipophilicity of salmeterol may produce a high effects showed a similar pattern with the lowest doses of salmeterol (100 g) and salbutamol myocardial reservoir and thus a greater and more prolonged cardiac response.
23 24
(600 g) having a similar profile to placebo whilst the highest dose of salmeterol (400 g) In conclusion, salmeterol was some eight times more potent than salbutamol for change had the most adverse effects, in keeping with its greater systemic effects and prolonged action. in QT c interval and plasma potassium concentration which suggests that, for peak systemic effects, salmeterol 100 g is broadly equivalent to salbutamol 800 g. The changes     Salmeterol is approximately 10 times more seen following salmeterol 100 g were small compared with placebo which is in keeping potent than salbutamol in relaxing pre-contracted tracheal tissue and in inhibiting airway with the low incidence of adverse effects seen in most clinical studies. The largest individual smooth muscle contraction, two 2 adrenoceptor mediated effects. 8 19 Our finding that changes seen after the lowest doses of both drugs for heart rate, QT c interval, plasma salmeterol was some 7-8 times more potent than salbutamol in producing 2 adrenoceptor potassium and glucose concentrations were +20 bpm, +53 ms, −0.8 mmol/l and mediated systemic effects (change in plasma potassium and QT c interval) is in keeping with +1.3 mmol/l, respectively, for salmeterol 100 g and +31 bpm, +76 ms, −0.5 mmol/l these data. Another possible explanation for our potency difference is that salmeterol has and +1.2 mmol/l for salbutamol 600 g. Our study was carried out in fit healthy young subgreater systemic bioavailability due to increased absorption from the lung, buccal mucosa, or jects and although most patients with asthma will demonstrate tachyphylaxis to the systemic decreased gastrointestinal tract first pass metabolism. At therapeutic doses the swallowed effects of regular salmeterol, some older subjects with other risk factors for cardiovascular fraction of salbutamol contributes relatively little to systemic effects due to its fairly high adverse effects may show larger changes with therapeutic doses of salmeterol. The relatively first pass metabolism; 20 21 the extent of first pass metabolism for salmeterol is unknown. steep dose response curves for salmeterol show that it has a relatively small therapeutic window Absorption from the lung is affected by the size and site of deposition of particles from an and support the current recommendations that salmeterol should be prescribed at the inhaler and a third possible explanation for our findings is that more drug was deposited per lowest effective dose and that a twice daily rather than "as required" dose regimen is appuff from the metered dose inhaler delivering salmeterol than that delivering salbutamol, re-propriate. sulting in greater absorption of salmeterol into
The authors would like to thank Glaxo Wellcome, Greenford, the systemic circulation. 22 On balance, how-UK who supported the study, in particular Choy Man for ever, it seems likely that the high relative dose technical support and Oliver Keene and Jan McRae (Medical Statistics Department) for generating the random code and potencies are due to true differences in potency assistance with statistical analysis. rather than differences in systemic absorption, although we are currently assessing the con- 
